» Articles » PMID: 30735165

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Overview
Journal J Vis Exp
Date 2019 Feb 9
PMID 30735165
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The use of mouse models is indispensable for studying the pathophysiology of various diseases. With respect to lung cancer, several models are available, including genetically engineered models as well as transplantation models. However, genetically engineered mouse models are time-consuming and expensive, whereas some orthotopic transplantation models are difficult to reproduce. Here, a non-invasive intratracheal delivery method of lung tumor cells as an alternative orthotopic transplantation model is described. The use of mouse lung adenocarcinoma cells and syngeneic graft recipients allows studying tumorigenesis under the presence of a fully active immune system. Furthermore, genetic manipulations of tumor cells before transplantation makes this model an attractive time-saving approach to study the impact of genetic factors on tumor growth and tumor cell gene expression profiles under physiological conditions. Using this model, we show that lung adenocarcinoma cells express increased levels of the T-cell suppressor programmed death-ligand 1 (PD-L1) when grown in their natural environment as compared to cultivation in vitro.

Citing Articles

RadioFlow Cytometry Reveals That [F]FDG Uptake in K-RAS Lung Cancer Is Driven by Immune Cells: An Analysis on a Single-Cell Level.

Vraka C, Homolya M, Ozer O, Spittler A, Machtinger M, Moll H J Nucl Med. 2025; 66(2):215-222.

PMID: 39819684 PMC: 11800735. DOI: 10.2967/jnumed.124.268799.


The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer.

Ghaddar N, Wang S, Woodvine B, Krishnamoorthy J, van Hoef V, Darini C Nat Commun. 2021; 12(1):4651.

PMID: 34330898 PMC: 8324901. DOI: 10.1038/s41467-021-24661-0.


Lung Adenocarcinoma Mouse Models Based on Orthotopic Transplantation of Syngeneic Tumor-Initiating Cells Expressing EpCAM, SCA-1, and Ly6d.

Semba T, Sato R, Kasuga A, Suina K, Shibata T, Kohno T Cancers (Basel). 2020; 12(12).

PMID: 33348616 PMC: 7767274. DOI: 10.3390/cancers12123805.